Document is current
Any future updates will be listed below
-
Authors
Fanucci, Kristina A. https://orcid.org/0000-0003-3400-7211
Bai, Yalai
Pelekanou, Vasiliki
Nahleh, Zeina A.
Shafi, Saba
Burela, Sneha
Barlow, William E.
Sharma, Priyanka https://orcid.org/0000-0001-8592-2239
Thompson, Alastair M.
Godwin, Andrew K. https://orcid.org/0000-0002-3987-9580
Rimm, David L. https://orcid.org/0000-0001-5820-4397
Hortobagyi, Gabriel N. https://orcid.org/0000-0002-4873-4412
Liu, Yihan
Wang, Leona
Wei, Wei
Pusztai, Lajos https://orcid.org/0000-0001-9632-6686
Blenman, Kim R. M. https://orcid.org/0000-0001-6070-0728
-
Funding
Funding for this research was provided by:
Susan G. Komen (SAC160076, SAC160076)
Breast Cancer Research Foundation (BCRF-21-133, To Dr David Rimm, BCRF-21-133)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U10CA180888, U10CA180819)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Genentech
Genentech (Roche), Abraxis BioScience (Celgene), and Helomics™
U.S. Department of Health & Human Services | National Institutes of Health (U10CA180888, U10CA180819)
U.S. Department of Health & Human Services | National Institutes of Health
Celgene
- License Information
-
More Information
Article History
Received: 25 April 2022
Accepted: 11 April 2023
First Online: 13 May 2023
Competing interests
: L.P. has received consulting fees and honoraria from Pfizer, AstraZeneca, Merck, Novartis, Bristol-Myers Squibb, Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Clovis, Syndax, H3Bio, and Daiichi. D.L.R. reports grants and personal fees from Amgen, grants and personal fees from AstraZeneca, personal fees from Cell Signaling Technology, grants and personal fees from Cepheid, personal fees from Danaher, personal fees from Fluidigm, personal fees from GSK, grants and personal fees from Konica Minolta, grants and personal fees from Lilly, personal fees from Merck, personal fees from Monopteros, personal fees from NanoString, grants and personal fees from NextCure, personal fees from Odonate, personal fees from Paige.AI, personal fees from Regeneron, personal fees from Roche, personal fees from Sanofi, personal fees from Ventana, and personal fees from Verily outside the submitted work. A.K.G. is a co-founder of Sinochips Diagnostics, serves as a scientific advisory board member to Biovica, Clara Biotech, and Sinochips Diagnostics, and receives research funding from Predicine and VITRAC Therapeutics. V.P. is currently a Bayer Pharmaceuticals-US employee. P.S. has received consulting fees from Novartis, Merck, Seattle Genetics, Exact Biosciences, Epic Biosciences, Immunomedics, and AstraZeneca. P.S. had received research funding from Novartis, Celgene, Bristol-Myers Squibb, and Merck. A.T’s spouse is an employee of Eli Lilly. K.R.M.B. is on the Scientific Advisory Board of CDI Labs as a non-financial interest. The above and other authors declare no other competing financial or non-financial interests. This research was conducted with support from Genentech.
